The FDA granted accelerated approval to pembrolizumab (Keytruda, Merck) for the treatment of patients who have metastatic small cell lung cancer (SCLC) that progresses on or after platinum-based chemotherapy and at least one other line of therapy.
Pembrolizumab is “an additional treatment option for patients” who historically have had “limited treatment options,” said Patrick Ott, MD, PhD, the clinical director of Dana-Farber Cancer Institute’s Center for